NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed)
ID: 356018Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356018

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-269.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the NIDA Animal Genomics Program (U01), aimed at investigating genetic, genomic, and molecular variants associated with substance use disorders (SUD). The program seeks to identify the genetic architecture influencing neural and behavioral traits related to SUD risk, trajectories, and comorbidities, encouraging the use of diverse methodologies, including multi-omics and machine learning approaches. This initiative is critical for advancing the understanding of SUD and developing potential therapeutic targets for addiction treatment. Applications are due by February 11, 2027, with a funding period of up to five years and no budget limit, although costs must be justifiable. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-269.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-269.html
    The National Institute on Drug Abuse (NIDA) is inviting applications for the Animal Genomics Program (U01) to investigate the genetic, genomic, and molecular variants linked to substance use disorders (SUD). This program aims to identify the genetic architecture influencing neural and behavioral traits associated with SUD risk, trajectories, and comorbidities. Researchers are encouraged to employ a variety of approaches, including multi-omics and machine learning, to explore genetic mechanisms that may reveal therapeutic targets for addiction treatment. A Plan for Enhancing Diverse Perspectives (PEDP) is a mandatory requirement for application, reflecting the NIH's commitment to inclusivity in research. Application deadlines begin on January 11, 2025, with a funding period of up to five years and no limit on the budget, although costs must be justifiable. Eligible applicants encompass a wide range of organizations, including public and private institutions, nonprofits, and foreign entities. The review process will evaluate the scientific merit, innovation, and feasibility of proposals, emphasizing interdisciplinary collaboration. Successful applications will contribute significantly to understanding SUD and enhancing future research efforts in addiction science.
    Similar Opportunities
    Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders" (R21/R33), aimed at supporting research projects that explore the genetic underpinnings of substance use disorders. This initiative encourages researchers to utilize innovative methodologies, such as CRISPR technologies, to validate addiction-relevant genes and characterize their roles in living organisms or human organoid systems, thereby enhancing the understanding of neurobiological mechanisms associated with addiction. The funding allows for up to $125,000 per year for the R21 phase over two years and up to $250,000 annually for the R33 phase over three years, with applications due by 5:00 PM local time on February 3, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-267.html.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Avenir Award Program for early-stage investigators focused on the genetics or epigenetics of substance use disorders (SUDs). This grant program aims to support innovative research that has the potential to significantly advance the understanding of addiction, particularly for those researchers who may lack preliminary data typically required for larger grants. The funding opportunity, which totals up to $300,000 annually for a maximum of five years, encourages applications from a diverse range of eligible institutions, including historically underrepresented groups. Interested applicants can submit their proposals until September 25, 2025, and should refer to the full announcement for detailed submission guidelines and requirements, available at NIH Grants. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Integrated Functional Mapping and Molecular Profiling of Cell Ensembles Encoding the Effects of Addictive Substances in Rodents (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Integrated Functional Mapping and Molecular Profiling of Cell Ensembles Encoding the Effects of Addictive Substances in Rodents." This initiative aims to support innovative research that utilizes scalable technologies to investigate the cellular responses associated with substance use disorders in rodent models, focusing on integrating neural activity metrics with molecular profiles to enhance understanding of addiction-related neurobehavioral processes. The total funding available is $2 million, with individual grants not exceeding $700,000 in direct costs per year for a project period of up to five years, and proposals must adhere to NIH’s data sharing policies. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with the application deadline set for February 23, 2026.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)," aimed at advancing research on non-invasive brain stimulation (NIBS) as a treatment for substance use disorders (SUDs). This initiative encourages innovative proposals that explore novel NIBS targets and neurobiological responses, with a focus on understanding the mechanisms underlying SUDs through clinical trials involving human subjects. The NIH plans to allocate $1.5 million annually over three years to fund approximately six grants, with applications due by January 16, 2024. Interested applicants can find more information and guidance on the required Plan for Enhancing Diverse Perspectives (PEDP) at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)" aimed at advancing clinical research in the field of substance use disorders (SUD). The primary objective is to identify and validate novel targets for non-invasive brain stimulation (NIBS) and to explore the neurobiological, cognitive, and behavioral responses associated with NIBS that may lead to improved clinical outcomes such as reduced cravings or drug use. This initiative is crucial for enhancing understanding and treatment options for SUD through innovative research methodologies. Funding of up to $1.5 million is available for selected projects over a maximum project period of five years, with applications due by August 14, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application instructions available at the provided link.
    NIDA Program Project Grant Applications (P01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is inviting applications for Program Project Grants (P01 Clinical Trial Optional) aimed at fostering collaborative, multidisciplinary research on substance use disorders. Applicants must propose a minimum of three interrelated research projects that demonstrate scientific and administrative synergy under a unifying theme, addressing critical issues such as neuroscience, genetics, behavior, prevention, treatment, and health services related to substance use. This funding opportunity emphasizes inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) and encouraging participation from underrepresented groups, with a maximum project duration of five years. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by January 7, 2026.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for exploratory clinical neuroscience research focused on substance use disorders (SUD) through the R61/R33 phased innovation award mechanism. This funding opportunity aims to support clinical research proposals that investigate the neurobiological mechanisms underlying SUD, allowing for up to five years of funding, with the R61 phase dedicated to initial concept testing and the R33 phase contingent upon achieving specific milestones. The initiative is crucial for advancing understanding of substance abuse impacts in the U.S., encouraging innovative research on topics such as neural circuitry and cognitive factors influencing addiction. Interested applicants, including various educational and nonprofit institutions, can find more details and submit applications by the closing date of May 7, 2026, with no cost-sharing requirement. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-158.html.